About The Team

Our commercial and scientific backgrounds give us a comprehensive view of what it takes to succeed in the industry.  Our experience spans biopharma, diagnostics, and medical device clients, from start-ups to the major players, across dozens of therapeutic areas.

Michael Schlamp, Principal

Mike has more than 20 years of experience in biopharma commercialization and business development on both the industry side (Actelion, Genentech, Acologix) and the consulting side (ZS Associates). He has experience in commercial strategy, market research, forecasting, launch planning, and reimbursement planning for a range of programs from in-line to pre-IND. He has assisted companies ranging from Fortune 100 Big Pharmas to private biotechs across a wide range of therapeutic areas (including oncology, CNS, pain, cardiology, pulmonary hypertension, immunology, asthma/ COPD, nephrology, neurodegenerative disease, gastroenterology, and ultra-orphan). Mike has a BS from MIT and a Ph.D. in Chemistry from the University of California, Berkeley.

Alan Aimi, Principal

Alan has more than 20 years in biotechnology commercial strategic planning, commercialization and business development. He has worked at Actelion, Genentech and Hyperion Therapeutics in the areas of launch planning; launch execution, life cycle planning and market assessments/in-licensing. Alan has successfully led launches in immunology and ultra-orphan diseases and has experience in numerous other therapeutic areas including oncology, neurology, pulmonology, cardiology, nephrology and rheumatology. Alan has a B.S. from the University of Colorado and an MBA from the University of Queensland, Australia.

Suzanne Ochoa, Principal 

Suzanne brings over 20 years of experience in pharmaceuticals, medical devices/hospital equipment, and veterinary medicine. Her functional expertise includes developing and managing market research across the product lifespan, as well as strategic support for commercial development and marketing teams. Suzanne started her career at Pfizer, Inc., where she held positions in Market Research, Brand Management and Regional Marketing. On the consulting side, she has worked with big Pharma clients, as well as biotech startups, on diverse therapeutic categories, including CNS, cardiology and metabolic disorders, infectious diseases, oncology and rare diseases. Suzanne holds a B.A. in English from Oberlin College, a Ph.D. in Anthropology from New York University, and a M.B.A. in Marketing from New York University, Stern School of Business.

Reid Bengard, Principal

Reid started conducting market research for biotechnology and pharmaceutical companies in 1997. His experience spans qualitative and quantitative studies across dozens of therapeutic categories, including actinic keratosis, anemia, bone fracture, breast cancer, CRC, diabetes, NSCLC, hemophilia, lymphomas, multiple myeloma, MS, neutropenia, prostate cancer, pain, psoriasis, and RA, among others. Prior to starting Aquest, Reid held senior positions at ZS Associates and Ziment. Reid has a BS from the University of California at Davis and an MBA from the Wharton School of the University of Pennsylvania.

Jim Thompson, Principal

Jim has more than 20 years of international pharmaceutical and biopharmaceutical strategy consulting experience. His areas of expertise are business planning, launch planning, market research and business development and has worked across a broad range of therapeutic areas, including autoimmune disorders, nephrology, neurology, oncology, ophthalmology, pulmonology and infectious diseases. Before joining Aquest, Jim was a Director with Navigant Consulting’s Life Science Strategy Practice. Prior to his role at Navigant, he was a Partner at Front Line Strategic Consulting and was instrumental in its growth and sale to Navigant Consulting. Jim has an MBA from U.C. Berkeley and a BA in molecular biology from San Jose State University.

Matt Voghel, Consultant

Matt has 5 years of experience in biopharma market research and commercial strategy consulting. His past work experience includes Ipsos, ZoomRx, and Boehringer Ingelheim. He specializes in both quantitative and qualitative market research, with a focus in oncology but experience in a wide range of therapeutic areas (including cardiology, neurology, immunology, vaccines, women’s health, and gastroenterology). Matt has an MBA and Pharm.D from the University of Connecticut.

Toby Kilroy, Consultant

Toby has more than 5 year of experience in biotechnology consulting. He has experience in commercial strategy, qualitative and quantitative market research, data analysis, and forecasting for a range of programs from preclinical to post-launch. He has worked with companies across a wide variety of therapeutic areas including oncology, neurology, and rare diseases. Toby has a BS from Case Western Reserve University and a joint MTM from UC Berkeley and UC San Francisco.

Cavan Bailey, Consultant

Cavan is a life science consultant experienced in market research and biotech commercialization. He has experience in autoimmunity, infectious disease, hematology, oncology, wound care, and ophthalmology. He also has extensive academic research experience in genetics, hematology, and oncology at top cancer centers. Cavan has a B.A. from Rutgers University and a Ph.D. from the University of Texas MD Anderson Cancer Center.

Michael Schlamp, Principal

Mike has more than 20 years of experience in biopharma commercialization and business development on both the industry side (Actelion, Genentech, Acologix) and the consulting side (ZS Associates). He has experience in commercial strategy, market research, forecasting, launch planning, and reimbursement planning for a range of programs from in-line to pre-IND. He has assisted companies ranging from Fortune 100 Big Pharmas to private biotechs across a wide range of therapeutic areas (including oncology, CNS, pain, cardiology, pulmonary hypertension, immunology, asthma/ COPD, nephrology, neurodegenerative disease, gastroenterology, and ultra-orphan). Mike has a BS from MIT and a Ph.D. in Chemistry from the University of California, Berkeley.

Alan Aimi, Principal

Alan has more than 20 years in biotechnology commercial strategic planning, commercialization and business development. He has worked at Actelion, Genentech and Hyperion Therapeutics in the areas of launch planning; launch execution, life cycle planning and market assessments/in-licensing. Alan has successfully led launches in immunology and ultra-orphan diseases and has experience in numerous other therapeutic areas including oncology, neurology, pulmonology, cardiology, nephrology and rheumatology. Alan has a B.S. from the University of Colorado and an MBA from the University of Queensland, Australia.

Suzanne Ochoa, Principal 

Suzanne brings over 20 years of experience in pharmaceuticals, medical devices/hospital equipment, and veterinary medicine. Her functional expertise includes developing and managing market research across the product lifespan, as well as strategic support for commercial development and marketing teams. Suzanne started her career at Pfizer, Inc., where she held positions in Market Research, Brand Management and Regional Marketing. On the consulting side, she has worked with big Pharma clients, as well as biotech startups, on diverse therapeutic categories, including CNS, cardiology and metabolic disorders, infectious diseases, oncology and rare diseases. Suzanne holds a B.A. in English from Oberlin College, a Ph.D. in Anthropology from New York University, and a M.B.A. in Marketing from New York University, Stern School of Business.

Reid Bengard, Principal

Reid started conducting market research for biotechnology and pharmaceutical companies in 1997. His experience spans qualitative and quantitative studies across dozens of therapeutic categories, including actinic keratosis, anemia, bone fracture, breast cancer, CRC, diabetes, NSCLC, hemophilia, lymphomas, multiple myeloma, MS, neutropenia, prostate cancer, pain, psoriasis, and RA, among others. Prior to starting Aquest, Reid held senior positions at ZS Associates and Ziment. Reid has a BS from the University of California at Davis and an MBA from the Wharton School of the University of Pennsylvania.

Jim Thompson, Principal

Jim has more than 20 years of international pharmaceutical and biopharmaceutical strategy consulting experience. His areas of expertise are business planning, launch planning, market research and business development and has worked across a broad range of therapeutic areas, including autoimmune disorders, nephrology, neurology, oncology, ophthalmology, pulmonology and infectious diseases. Before joining Aquest, Jim was a Director with Navigant Consulting’s Life Science Strategy Practice. Prior to his role at Navigant, he was a Partner at Front Line Strategic Consulting and was instrumental in its growth and sale to Navigant Consulting. Jim has an MBA from U.C. Berkeley and a BA in molecular biology from San Jose State University.

Matt Voghel, Consultant

Matt has 5 years of experience in biopharma market research and commercial strategy consulting. His past work experience includes Ipsos, ZoomRx, and Boehringer Ingelheim. He specializes in both quantitative and qualitative market research, with a focus in oncology but experience in a wide range of therapeutic areas (including cardiology, neurology, immunology, vaccines, women’s health, and gastroenterology). Matt has an MBA and Pharm.D from the University of Connecticut.

Toby Kilroy, Consultant

Toby has more than 5 year of experience in biotechnology consulting. He has experience in commercial strategy, qualitative and quantitative market research, data analysis, and forecasting for a range of programs from preclinical to post-launch. He has worked with companies across a wide variety of therapeutic areas including oncology, neurology, and rare diseases. Toby has a BS from Case Western Reserve University and a joint MTM from UC Berkeley and UC San Francisco.

Cavan Bailey, Consultant

Cavan is a life science consultant experienced in market research and biotech commercialization. He has experience in autoimmunity, infectious disease, hematology, oncology, wound care, and ophthalmology. He also has extensive academic research experience in genetics, hematology, and oncology at top cancer centers. Cavan has a B.A. from Rutgers University and a Ph.D. from the University of Texas MD Anderson Cancer Center.